Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials (P1-12.015)

Suzanne Hendrix; John Whetten; Kent Hendrix; Samuel Dickson

doi:10.1212/wnl.0000000000215643

June 9, 2026Neurology

Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials (P1-12.015)

View at Publisher

Ask AI

Bookmark

Share

Key Points

Assess the clinical benefits of continuing anti-amyloid therapy beyond plaque clearance in early Alzheimer’s disease.
Evaluated clinical benefits of extended anti-amyloid therapy beyond plaque clearance
Compared outcomes in subjects receiving continued treatment versus those stopping treatment
Continuing anti-amyloid therapy showed significantly greater clinical benefits post plaque clearance compared to stopping
Patients who continued treatment demonstrated improved cognitive outcomes as measured by relevant clinical scales

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Explores treatment benefits of anti-amyloid therapy in early Alzheimer's disease, suggesting important implications for treatment decisions.

Abstract

To understand the added clinical benefits of continuing an anti-amyloid therapy (AAT) beyond plaque clearance in early Alzheimer’s disease (AD) compared to stopping treatment, so HCPs can make better informed decisions about AD treatment approaches.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hendrix et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f05619b https://doi.org/10.1212/wnl.0000000000215643

View at Publisher

Ask AI

Bookmark

Share

Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials (P1-12.015)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials (P1-12.015)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading